Eye & ENT Research最新文献

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":100519,"journal":{"name":"Eye & ENT Research","volume":"3 1","pages":"37-40"},"PeriodicalIF":0.0,"publicationDate":"2026-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148089677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":100519,"journal":{"name":"Eye & ENT Research","volume":"3 1","pages":"29-32"},"PeriodicalIF":0.0,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148067549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of optimized postoperative drainage pressure combined with parathyroid function monitoring in enhanced recovery after surgery for thyroid cancer: A prospective randomized controlled study","authors":"Fa Zhang,&nbsp;Yan Li,&nbsp;Xiwei Zhang,&nbsp;Zhaoyang Wang,&nbsp;Boshizhang Peng,&nbsp;Mengxiao Wu,&nbsp;Shaoyan Liu,&nbsp;Dangui Yan,&nbsp;Zongmin Zhang,&nbsp;Changming An","doi":"10.1002/eer3.70024","DOIUrl":"https://doi.org/10.1002/eer3.70024","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Postoperative drainage management and hypocalcemia monitoring are critical factors influencing enhanced recovery after surgery (ERAS) following thyroidectomy. This study aimed to evaluate the effects of different drainage pressures on postoperative drainage volume and hospitalization duration, and to explore the predictive value of parathyroid hormone (PTH) levels for hypocalcemia. The goal was to develop a multidimensional ERAS strategy for thyroid cancer patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This prospective randomized controlled trial enrolled 211 patients undergoing thyroidectomy. Participants were randomly allocated into three groups based on drainage pressure. Postoperative drainage volume, hospitalization duration, and complications were recorded. For patients undergoing total thyroidectomy, PTH and serum calcium levels were measured postoperatively. The optimal PTH cut-off value was determined using receiver operating characteristic curve analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The low-pressure group exhibited significantly reduced postoperative drainage volume on day 1 (6.54 ± 9.53 mL) compared to the medium- and high-pressure groups (34.07 ± 19.05 mL and 32.41 ± 20.72 mL). Drainage removal time (1.06 ± 0.23 days) and hospitalization duration (1.26 ± 0.47 days) were also shorter in the low-pressure group. A postoperative 2-h PTH level ≤ 6.985 pg/mL effectively predicted hypocalcemia (sensitivity 79.4%, specificity 91.0%). The combined ERAS protocol further reduced hospitalization duration and significantly lowered postoperative Visual Analog Scale scores (0.85 ± 0.75) without increasing complication rates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Low-pressure drainage reduces postoperative drainage volume and accelerates recovery in thyroid cancer patients. A 2-h postoperative PTH level ≤ 6.985 pg/mL serves as a reliable predictor for hypocalcemia. The combined strategy of optimized drainage pressure and PTH monitoring provides a safe and effective ERAS pathway for thyroid surgery.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100519,"journal":{"name":"Eye & ENT Research","volume":"2 3","pages":"221-230"},"PeriodicalIF":0.0,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eer3.70024","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145171982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report and surgical technique—Nasal mass seen in Zimmermann-Laband syndrome","authors":"Grant Gochman,&nbsp;Danae Alexandrou,&nbsp;Amy Pittman","doi":"10.1002/eer3.70025","DOIUrl":"https://doi.org/10.1002/eer3.70025","url":null,"abstract":"&lt;p&gt;Nasal masses are a common finding in the field of otolaryngology, and they may be congenital, inflammatory, neoplastic, or from trauma [&lt;span&gt;1&lt;/span&gt;]. Depending on location, they may cause a change in smell, congestion, obstruction, nasal drainage, or epistaxis. Common, benign nasal masses include polyps, dermoid cysts, rhinophyma and others. More serious presentations may include malignancies or underlying genetic conditions.&lt;/p&gt;&lt;p&gt;This case report describes a unique presentation of an 18-year-old with concern for Zimmermann-Laband syndrome (ZLS). ZLS is a rare, autosomal dominant genetic disorder, that is predicted to affect less than 1/1,000,000 of the population. ZLS is generally characterised by gingival hypertrophy, hypoplastic/aplastic nails, joint hyperextensibility, hirsutism/hypertrichosis, and craniofacial abnormalities, especially of the nose or ears [&lt;span&gt;2&lt;/span&gt;]. Within the literature, a wide variety of symptoms are described, with presentation onset between birth and childhood [&lt;span&gt;3&lt;/span&gt;]. Due to its ambiguous presentation, timely diagnosis may be difficult. Dentists and oral surgeons may play a significant role in identifying early presentations of ZLS, but genetic consultation is crucial. Underlying genetic mutations in &lt;i&gt;KCNH1&lt;/i&gt;, &lt;i&gt;KCNN3&lt;/i&gt;, and &lt;i&gt;ATP6V1B2&lt;/i&gt; have been described, however these is a great deal of variability in involved gene mutations [&lt;span&gt;3&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Treatment for ZLS includes managing abnormal gingival or craniofacial growths through surgical intervention, as well as lifelong medical management of symptoms and disease progression. Gingival hypertrophy, in particular, requires intensive orthodontic and surgical management, often requiring multiple procedures [&lt;span&gt;4&lt;/span&gt;]. No studies in the current literature describes surgical management of a bulbous nose, or rhinophyma, characterised in multiple case reports of ZLS [&lt;span&gt;5&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;We describe an 18-year-old male who presented to clinic for evaluation of enlarging nasal growths over two years. They originated as small, scattered pustules with occasional purulent discharge. He also experienced nasal congestion. Since birth, he has had increased facial and body hair growth. Since 9 months old, he has undergone six orthodontic surgeries for gingival hyperplasia. He has no history of asthma, trauma to the face, or prior otolaryngologic surgery. On physical exam, hyperextensibility of joints were noted, with no evidence of hypoplastic/aplastic nails. Soft, compressible, nontender, fibromatous growths and sebaceous hyperplasia overlying the nasal tip, dorsum, and ala were noted (Figure 1). He also had gingival and tonsillar hypertrophy as well as significant hypertrichosis of the face, hands, and feet.&lt;/p&gt;&lt;p&gt;Given his physical exam findings concerning for ZLS, he underwent genetic testing for the &lt;i&gt;KCNH1&lt;/i&gt;, &lt;i&gt;KCNN3&lt;/i&gt;, and &lt;i&gt;ATP6V1B2&lt;/i&gt; genes. Results were negative for any pathogenic mutations. Our patient also underwent i","PeriodicalId":100519,"journal":{"name":"Eye & ENT Research","volume":"2 3","pages":"231-233"},"PeriodicalIF":0.0,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eer3.70025","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145171962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting thymic stromal lymphopoietin in nasal type 2 inflammation","authors":"Xintong Li,&nbsp;Jingjing Guo,&nbsp;Jing Song,&nbsp;Ming Wang","doi":"10.1002/eer3.70023","DOIUrl":"https://doi.org/10.1002/eer3.70023","url":null,"abstract":"<p>Epithelial cell-derived thymic stromal lymphopoietin (TSLP) plays a crucial role in mediating type 2 immune responses, which is one of the key underlying pathophysiological mechanisms of allergic rhinitis (AR) and most presentations of chronic rhinosinusitis with nasal polyps (CRSwNP). Researches show that inhibiting TSLP signaling has significant therapeutic potential in alleviating type 2 inflammation. Biologics targeting TSLP have been developed and introduced into clinical practice, yielding promising therapeutic outcomes, especially in asthma. Several anti-TSLP antibodies are undergoing clinical trials to investigate the efficacy and safety in treating CRSwNP and AR. This review aims to delve into the latest progress regarding the functional role of TSLP, the clinical outcomes associated with anti-TSLP therapies, and the therapeutic potential of anti-TSLP antibodies in treating nasal type 2 inflammation.</p>","PeriodicalId":100519,"journal":{"name":"Eye & ENT Research","volume":"2 3","pages":"164-172"},"PeriodicalIF":0.0,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eer3.70023","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145172065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the mechanisms of capsicum in age-related hearing loss: Based on network pharmacology","authors":"Yan Wang,&nbsp;Xiaoyu Song,&nbsp;Fengxin Yang,&nbsp;Huhuifen He,&nbsp;Kun Zhao,&nbsp;Jingjing Qiu,&nbsp;Limei Cui,&nbsp;Qiang Zhang,&nbsp;Limei Liu,&nbsp;Yan Sun","doi":"10.1002/eer3.70021","DOIUrl":"https://doi.org/10.1002/eer3.70021","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To explore the material basis and action mechanism of the chemical component gene of pepper on presbycusis, and to provide a reference for the traditional Chinese medicine treatment of age-related hearing loss (ARHL).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The chemical composition and action targets of traditional Chinese medicine flavor of pepper were searched using the Traditional Chinese Medicine System Pharmacological database. Disease targets for ARHL were identified through the GeneCards database. The interaction relationship of the “drug-component-target-pathway” network and potential targets were constructed using Cytoscape software, and the mechanism of action was predicted by enrichment analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>As a result, 6 active components, 36 drug targets and 1100 disease targets of presbycusis were excavated, and 26 drug-disease common targets were obtained, with the key targets including CTNNB1, GSK-3β, GJA1, AKT1, MYC, BCL2. A total of 254 entries were obtained by GO enrichment analysis, which mainly involved neuronal apoptotic process, apoptotic process, and extracellular signalling process. KEGG pathways were enriched to select 72 signal pathways, including P53 signaling pathway, comprehensive cancer pathway, TNF-α signaling pathway, neurodegenerative disease regulatory pathway, cell apoptosis pathway, etc. The molecular docking results showed that the folic acid (FA) family has a good binding ability with GSK-3β.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In conclusion, capsicum may exert a suppressive effect on the occurrence and progression of ARHL through multiple pathways. Its main component, FA, demonstrates a strong binding affinity with GSK-3β, suggesting that it could serve as a potential therapeutic target for presbycusis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100519,"journal":{"name":"Eye & ENT Research","volume":"2 3","pages":"202-214"},"PeriodicalIF":0.0,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eer3.70021","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145171990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence, severity and factors of hearing loss in hemodialysis patients: A cross-sectional study in Northern Tanzania","authors":"Abdallah Jonas,&nbsp;Denis Katundu,&nbsp;Johnson Shayo,&nbsp;Petro Nsalu,&nbsp;Ezekiel Karuga,&nbsp;Kajiru Kilonzo,&nbsp;Peter Shija","doi":"10.1002/eer3.70022","DOIUrl":"https://doi.org/10.1002/eer3.70022","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hearing loss, affecting 20% of the global population, disproportionately impacts low- and middle-income countries, including Africa. Sensorineural hearing loss (SNHL) is prevalent among hemodialysis patients. In Tanzania, the growing number of hemodialysis patients highlights the need for hearing assessments. Previous studies may have underestimated hearing loss prevalence by excluding key comorbidities like diabetes and hypertension.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To determine the prevalence, severity, and associated factors of hearing loss among patients undergoing hemodialysis at Kilimanjaro Christian Medical Center (KCMC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This analytical hospital-based cross-sectional study was conducted at KCMC using a convenient sampling technique. Demographic and clinical data, including histories of renal disease, diabetes, hypertension, HIV, autoimmune diseases, and medication use, were collected via a structured questionnaire. Basic audiological assessments were performed using a pure-tone audiometer. Data were analyzed using univariate and multivariate logistic regression with IBM SPSS Statistics (version 25).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Bilateral SNHL was observed in 38.2% of patients, with 57.2% experiencing mild hearing loss, 35.7% moderate hearing loss, and 7.1% moderately severe hearing loss. Factors associated with hearing loss included advanced age (&gt;60 years), longer duration on hemodialysis, hypertension, and diabetes mellitus.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Mild bilateral SNHL was prevalent among hemodialysis patients. Key factors contributing to hearing loss were older age, prolonged hemodialysis, diabetes, and hypertension. Implementing a protocol for regular hearing assessments in this population is essential.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100519,"journal":{"name":"Eye & ENT Research","volume":"2 3","pages":"215-220"},"PeriodicalIF":0.0,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eer3.70022","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145171991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EZH2 negatively regulates IL-8 expression in human nasal epithelial cells through its histone methyltransferase activity","authors":"Yu Song,&nbsp;Minghang Yu,&nbsp;Yuan Zhang,&nbsp;Xi Wang,&nbsp;Xiangyi Liu","doi":"10.1002/eer3.70020","DOIUrl":"https://doi.org/10.1002/eer3.70020","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chronic rhinosinusitis (CRS), characterized by persistent inflammation of the nasal and sinus mucosa, exhibits an escalating global prevalence and incidence. Interleukin-8 (IL-8), a key chemokine driving neutrophil recruitment, is implicated in CRS pathogenesis. While non-epigenetic mechanisms of <i>IL8</i> regulation have been reported, the epigenetic landscape governing <i>IL8</i> expression in CRS remains unexplored.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to investigate the epigenetic regulation of IL-8 expression in human nasal epithelial cells (HNEpCs) with a focus on histone modification-mediated mechanisms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Tumor necrosis factor-alpha (TNF-α) was selected as a prototypical pro-inflammatory stimulus through systematic screening. An in vitro model of IL-8 induction was established and validated in TNF-α-treated HNEpCs. Regulatory mechanisms were probed using bioinformatics tools (UCSC Genome Browser, Cistrome DB) and pharmacological inhibitors targeting histone-modifying enzymes. siRNA-mediated enhancer of zeste homolog 2 (EZH2) knockdown to assess its regulatory role in IL-8 expression; Chromatin Immunoprecipitation followed by quantitative PCR (ChIP-qPCR) to determine whether H3K27me3 is directly enriched at the <i>IL8</i> promoter region under TNF-α stimulation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>TNF-α stimulation induced time and concentration-dependent upregulation of IL-8 mRNA (<i>p</i> &lt; 0.001) and protein secretion (<i>p</i> &lt; 0.001) in HNEpCs. TNF-α-mediated IL-8 upregulation was abrogated by the addition of methyltransferase inhibitors EPZ005687, EPZ6438, and BIX01294. SiRNA-mediated EZH2 depletion significantly enhanced both IL-8 mRNA (<i>p</i> &lt; 0.001) and protein levels (<i>p</i> &lt; 0.01). ChIP-qPCR confirmed TNF-α-dependent enrichment of H3K27me3 at the <i>IL8</i> promoter, supporting EZH2-mediated transcriptional repression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>EZH2-dependent H3K27 trimethylation is a key epigenetic mechanism controlling IL-8 gene expression in HNEpCs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100519,"journal":{"name":"Eye & ENT Research","volume":"2 3","pages":"194-201"},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eer3.70020","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145171963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ipsilateral cochlear implantation in cases with vestibular schwannoma","authors":"Qian Wan,&nbsp;Ruotong Wang,&nbsp;Yaqin Wu,&nbsp;Dongzhen Yu,&nbsp;Haibo Shi,&nbsp;Jingjing Wang,&nbsp;Pengjun Wang,&nbsp;Zhengnong Chen","doi":"10.1002/eer3.70019","DOIUrl":"https://doi.org/10.1002/eer3.70019","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Vestibular schwannomas (VS) are the most common tumors in the cerebellopontine angle, which can lead to hearing loss, particularly following tumor resection. For patients with bilateral VS associated with neurofibromatosis type 2 (NF2), hearing loss significantly undermines their quality of life.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aims to evaluate the outcomes of ipsilateral cochlear implantation (CI) in patients with VS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>We assessed six patients with VS, three of whom were diagnosed with NF2. Four patients underwent VS resection combined with simultaneous ipsilateral CI. Two patients received CI without tumor removal. Electrically evoked auditory brainstem response (eABR) testing was employed to assess the functionality of the cochlear nerve during the resection procedure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Simultaneous ipsilateral CI following VS resection was performed in four patients who underwent tumor removal, and cochlear nerve function was identified using eABR testing. Two patients without tumor resection also had implantations. The average impedance of the test electrodes was within the normal range and neural telemetry responses were detected in all patients. One patient opted out of using the cochlear due to normal hearing in the contralateral ear and found the implant unbeneficial. The remaining five patients experienced improvements in hearing, albeit to varying degrees.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Simultaneous ipsilateral CI after VS resection is an effective approach for auditory rehabilitation. For NF2 patients with small, stable tumors, CI without tumor removal can also be considered a viable option. This study highlights the potential of CI in hearing rehabilitation for patients with VS, particularly those with NF2.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100519,"journal":{"name":"Eye & ENT Research","volume":"2 3","pages":"185-193"},"PeriodicalIF":0.0,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eer3.70019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145171923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Think highly of immunoglobulin G4-related chronic rhinosinusitis as a clinical entity in immunoglobulin G4-related disease","authors":"Lianqi Wan,&nbsp;Luo Zhang,&nbsp;Yingshi Piao,&nbsp;Yuan Zhang","doi":"10.1002/eer3.70018","DOIUrl":"https://doi.org/10.1002/eer3.70018","url":null,"abstract":"<p>IgG4-related chronic rhinosinusitis (IgG4-related CRS) is gaining recognition among various specialized physicians. As a systemic disease involving multiple organs, IgG4-related CRS is still not widely recognized as an independent clinical entity. Given the complexity of diagnosing autoimmune-related multisystem diseases, early recognition and diagnosis of IgG4-related CRS have become more challenging. Despite being an independent clinical entity, IgG4-related CRS is still mainly understood only by otolaryngologists but not other specialists. Here we reviewed studies related to the gradual recognition, the diagnostic controversies and challenges, treatment progress, pathogenesis, and current knowledge of IgG4-related CRS.</p>","PeriodicalId":100519,"journal":{"name":"Eye & ENT Research","volume":"2 3","pages":"151-163"},"PeriodicalIF":0.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eer3.70018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145171942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}